Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Table 1 Demographic and clinical characteristics of patients prior to hepatitis c treatment n (%)

Characteristics	n = 736
Age, mean ± SD (yr)	58 ± 10
Range	(23-85)
Male sex	403 (55)
Ethnicity
Caucasian	374 (51)
African American	178 (24)
Hispanic	158 (21)
Asian/Pacific islanders	26 (4)
HCV genotype-subtype
1a	475 (64)
1b	242 (33)
1 without confirmed subtype	19 (3)
Liver biopsy	317 (43)
Vibration-controlled transient elastography	25 (3)
FIBROSpect II	3 (0.4)
Overall fibrosis score
Stage 0	45 (13)
Stage 1	164 (48)
Stage 2	104 (30)
Stage 3	29 (8)
Stage 3-4 or 4	2 (1)
Non-cirrhotic state determined by clinical judgement	391 (53)
HCV RNA - log10 IU/mL, mean ± SD	6.2 ± 0.2
HCV RNA ≥ 2.2 million IU/mL	219 (30)
Pre-treatment laboratory values
GFR, mean ± SD (Range)	79 ± 11 (40-89)
Platelet count (103/mm3), mean ± SD (Range)	218 ± 55 (45-495)
INR, mean ± SD (Range)	0.99 ± 0.7 (0.8-1.3)
Albumin, mean ± SD (Range)	3.9 ± 0.4 (2.1-5.1)
Missing	101 (14.0)
Co-morbid conditions
Psychiatric diagnoses	145 (20.0)
Chronic kidney disease	35 (5.0)
Psoriasis	16 (2.0)
HIV co-infection	5 (0.7)
Cryoglobulinemia	4 (0.5)
HCV-related glomerulonephritis	2 (0.3)
HBV co-infection	2 (0.3)
Hepatocellular carcinoma	1 (0.1)

HCV: Hepatitis C virus; HBV: Hepatitis B virus; GFR: Glomerular filtration rate; INR: International normalized ration; HIV: Human immunodeficiency virus.